Argo Biopharma Recognized Among World's Most Innovative Companies by Fast Company in 2026 Argo Biopharma has been named one of the World's Most Innovative Companies by Fast Company for 2026, showcasing its commitment to groundbreaking therapeutic advancements.

Argo Biopharma Recognized Among World's Most Innovative Companies by Fast Company in 2026 #China #Shanghai #Innovation #Argo_Biopharma #siRNA

Argo Biopharma Achieves FDA Fast Track Designation for Novel siRNA Therapy Targeting HAE Argo Biopharmaceutical Co., Ltd. has been awarded FDA Fast Track Designation for BW-20805, a promising siRNA therapy aimed at treating hereditary angioedema (HAE).

Argo Biopharma Achieves FDA Fast Track Designation for Novel siRNA Therapy Targeting HAE #HAE #Argo_Biopharma #BW-20805

Argo Biopharma Welcomes Dr. Gena Wang as CFO and Chief Strategy Officer Argo Biopharma has appointed Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer to propel its siRNA therapeutic development forward.

Argo Biopharma Welcomes Dr. Gena Wang as CFO and Chief Strategy Officer #None #Argo_Biopharma #siRNA_therapies #Dr._Gena_Wang

Argo Biopharma Showcases Promising Phase II Data for siRNA Therapy at AAAAI Annual Meeting Argo Biopharma will present promising interim Phase II results for its siRNA therapeutic BW-20805 targeting hereditary angioedema at the AAAAI Annual Meeting.

Argo Biopharma Showcases Promising Phase II Data for siRNA Therapy at AAAAI Annual Meeting #China #Shanghai #HAE #Argo_Biopharma #BW-20805

Argo Biopharma Initiates Groundbreaking Phase 2b Trial for siRNA Therapeutic BW-20829 Targeting Elevated Lp(a) Levels Argo Biopharma reports the first patient has been dosed in a pivotal Phase 2b trial of BW-20829, a cutting-edge siRNA therapy targeting cardiovascular conditions.

Argo Biopharma Initiates Groundbreaking Phase 2b Trial for siRNA Therapeutic BW-20829 Targeting Elevated Lp(a) Levels #China #Shanghai #Lp(a) #Argo_Biopharma #BW-20829

Argo Biopharma Set to Showcase Innovations at J.P. Morgan Healthcare Conference 2026 Argo Biopharma will present significant advancements in siRNA therapies at the 44th Annual J.P. Morgan Healthcare Conference in January 2026.

Argo Biopharma Set to Showcase Innovations at J.P. Morgan Healthcare Conference 2026 #United_States #San_Francisco #Healthcare_Conference #Argo_Biopharma #siRNA_therapies

Argo Biopharma Unveils Promising Phase I Results for HAE Treatment BW-20805 at ACAAI 2025 Argo Biopharma presents positive Phase I trial results for BW-20805, an innovative siRNA therapy targeting hereditary angioedema at ACAAI 2025.

Argo Biopharma Unveils Promising Phase I Results for HAE Treatment BW-20805 at ACAAI 2025 #USA #Orlando #HAE #Argo_Biopharma #BW-20805

Argo Biopharma Secures IND Approval for Phase II Trials of siRNA Therapy BW-40202 Targeting PNH Argo Biopharma announces IND approval from China's NMPA for Phase II trial of BW-40202, aiming to treat PNH and enhance patient outcomes with innovative siRNA therapy.

Argo Biopharma Secures IND Approval for Phase II Trials of siRNA Therapy BW-40202 Targeting PNH #China #Shanghai #PNH #Argo_Biopharma #BW-40202

Argo Biopharma Enters New Strategic Partnership with Novartis for Cardiovascular Innovations Argo Biopharma has sealed a significant collaboration with Novartis for cardiovascular drug development, enhancing their innovative capabilities in this sector.

Argo Biopharma Enters New Strategic Partnership with Novartis for Cardiovascular Innovations #China #Shanghai #Cardiovascular #Novartis #Argo_Biopharma